Ed Kensik11.29.06
Possis Medical stock shares surged after the medical device manufacturer received marketing clearance from the FDA for its AngioJet Xpeedior catheter.
The Minneapolis, MN-based company's stock added $1.84, or 16.1%, to $13.25 in electronic premarket trading on the INET electronic exchange on Wednesday.
The catheter is used to remove blood clots, or thrombus, from upper- and lower-extremity peripheral veins 3 millimeters or larger in diameter. The device is also cleared for general peripheral vascular use with Power Pulse Delivery, a procedure that sprays smaller doses of clot-dissolving medicine directly into the clot and then removes the softened clot material.
"This gives doctors a powerful tool to restore flow to blocked veins. Patients may benefit from faster resolution of leg pain and reduced risk of complications," CEO Robert Dutcher said in a statement.
The Minneapolis, MN-based company's stock added $1.84, or 16.1%, to $13.25 in electronic premarket trading on the INET electronic exchange on Wednesday.
The catheter is used to remove blood clots, or thrombus, from upper- and lower-extremity peripheral veins 3 millimeters or larger in diameter. The device is also cleared for general peripheral vascular use with Power Pulse Delivery, a procedure that sprays smaller doses of clot-dissolving medicine directly into the clot and then removes the softened clot material.
"This gives doctors a powerful tool to restore flow to blocked veins. Patients may benefit from faster resolution of leg pain and reduced risk of complications," CEO Robert Dutcher said in a statement.